Psychopharmacology

, Volume 204, Issue 1, pp 177–184

Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics

  • Xiang Yang Zhang
  • Dong Feng Zhou
  • Ling Yan Qi
  • Song Chen
  • Lian Yuan Cao
  • Da Chun Chen
  • Mei Hong Xiu
  • Fan Wang
  • Gui Ying Wu
  • Lin Lu
  • Therese A. Kosten
  • Thomas R. Kosten
Original Investigation

Abstract

Objective

Both schizophrenia and oxidative stress have been associated with immune system abnormalities in interleukin-2 and -6 (IL-2; IL-6) and increases in superoxide dismutase (SOD) activity. These abnormalities may improve during antipsychotic drug treatment that reduces symptoms in schizophrenic patients.

Materials and methods

Subjects included 30 healthy controls (HC) and 78 schizophrenic (SCH) in-patients who were randomly assigned to 12 weeks of double-blind treatment with risperidone 6 mg/day or haloperidol 20 mg/day. Ratings using the Positive and Negative Syndrome Scale (PANSS) were correlated with blood SOD and serum IL-2 levels.

Results

SCH patients who were medication-free for 2 weeks had greater SOD, IL-2, and IL-6 levels than HC. At baseline, these SOD elevations were associated with higher PANSS total scores and the IL-2 elevations with lower PANSS positive symptom scores. The SOD and IL-2 levels in the SCH were also positively correlated. After treatment, PANSS positive symptoms and both SOD and IL-2 showed a significant decrease, but IL-6 showed no change. The SOD and IL-2 reductions were correlated with the reductions in PANSS total score, and SOD reductions also correlated with positive subscore reductions. Females showed these associations more strongly than males.

Conclusion

Our results suggest that the dysregulation in the cytokine system and oxidative stress in patients with schizophrenia is implicated in clinical symptoms and is improved at least partially with antipsychotic treatment. The stronger associations in females deserve further study and confirmation.

Keywords

Schizophrenia Immune Cytokine Oxidative stress Antioxidant enzymes Antipsychotic Psychopathology 

References

  1. Arolt V, Rothermundt M, Wandinger KP, Kirchner H (2000) Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5:150–158PubMedCrossRefGoogle Scholar
  2. Baeuerle PA, Rupec RA, Pahl HL (1996) Reactive oxygen intermediates as second messengers of a general pathogen response. Pathol Biol 44:29–35PubMedGoogle Scholar
  3. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A (1995) Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38:297–302PubMedCrossRefGoogle Scholar
  4. Bleich A, Brown SL, Kahn R, van Praag HM (1988) The role of serotonin in schizophrenia. Schizophr Bull 14:297–315PubMedGoogle Scholar
  5. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A, Clerici M (2001) Cytokine profiles in drugnaive schizophrenic patients. Schizophr Res 47:293–298PubMedCrossRefGoogle Scholar
  6. Dröge W, Eck HP, Gmünder H, Mihm S (1991) Requirement for prooxidant and antioxidant states in T cell mediated immune responses. Relevance for the pathogenetic mechanisms of AIDS? Klin Wochenschr 15(69):1118–1122CrossRefGoogle Scholar
  7. Dröge W, Eck HP, Mihm S (1994) Oxidant-antioxidant status in human immunodeficiency virus infection. Methods Enzymol 233:594–601PubMedCrossRefGoogle Scholar
  8. Eugui EM, DeLustro B, Rouhafza S, Ilnicka M, Lee SW, Wilhelm R, Allison AC (1994) Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-alpha, IL-beta, and IL-6 by human peripheral blood mononuclear cells. Int Immunol 6:409–422PubMedCrossRefGoogle Scholar
  9. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454PubMedCrossRefGoogle Scholar
  10. Ganguli R, Yang Z, Shurin G, Chengappa RKN, Brar JS, Gubbi AV, Rabin BS (1994) Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51:1–10PubMedCrossRefGoogle Scholar
  11. Ganguli R, Brar JS, Chengappa KNR, Deleo M, Yang ZW, Shurin G (1995) Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch Gen Psychiatry 52:668–672PubMedGoogle Scholar
  12. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6:66–73PubMedCrossRefGoogle Scholar
  13. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M (1991) Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30:795–805PubMedCrossRefGoogle Scholar
  14. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693PubMedGoogle Scholar
  15. Kim YK, Kim L, Lee MS (2000) Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44:165–175PubMedCrossRefGoogle Scholar
  16. Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157:683–694PubMedCrossRefGoogle Scholar
  17. Lapchak PA (1992) A role of interleukin-2 in the regulation of striatal dopamingergic function. NeuroReport 3:165–168PubMedCrossRefGoogle Scholar
  18. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150:1408–1410PubMedGoogle Scholar
  19. Lin A, Kenis G, Bignotti S, Tura GJ, DeJong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32:9–15PubMedCrossRefGoogle Scholar
  20. Lohr JB (1991) Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 48:1097–1106PubMedGoogle Scholar
  21. Lohr JK, Flynn K (1992) Smoking and schizophrenia. Schizophr Res 8:93–102PubMedCrossRefGoogle Scholar
  22. Lohr JB, Browning JA (1995) Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 31:159–165PubMedGoogle Scholar
  23. Lohr JB, Underhill S, Moir S, Jeste DV (1990) Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28:535–539PubMedCrossRefGoogle Scholar
  24. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer H (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stablizers. J Psychiatr Res 29:141–152PubMedCrossRefGoogle Scholar
  25. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221–225PubMedCrossRefGoogle Scholar
  26. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F, Kenis G, Bosmans E, de Jongh R, Lin A, Racagni G, Altamura CA (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10:119–124PubMedCrossRefGoogle Scholar
  27. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 159:1291–1297Google Scholar
  28. Mahadik SP, Mukherjee S (1996) Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19:1–17PubMedCrossRefGoogle Scholar
  29. Mahadik SP, Mukherjee S, Correnti EE, Scheffer R, Mahadik J (1998) Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43:674–679PubMedCrossRefGoogle Scholar
  30. McCreadie RG, Macdonald E, Wiles D, Campbell G, Pateson JR (1995) The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects. Br J Psychiatry 167:1–8CrossRefGoogle Scholar
  31. Mukherjee S, Mahadik SP, Scheefer R, Correnti EE, Kelkar H (1996) Impaired antioxidant defense at the onset of psychosis. Schizophr Res 19:19–26CrossRefGoogle Scholar
  32. Muller N, Reidel M, Ackenheil M, Schwarz MJ (1999) The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249(suppl. 4):62–68PubMedGoogle Scholar
  33. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29:227–232PubMedCrossRefGoogle Scholar
  34. Peet M, Laugharne JD, Mellor J, Ramchand CN (1996) Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 55:71–75PubMedCrossRefGoogle Scholar
  35. Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J (1997) Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 154:1763–1765PubMedGoogle Scholar
  36. Ponizovsky AM, Modai I, Nechamkin Y, Barshtein G, Ritsner MS, Yedgar S, Lecht S, Bergelson LD (2001) Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology. Schizophr Res 52:121–126PubMedCrossRefGoogle Scholar
  37. Reddy RD, Yao JK (1996) Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 55:33–43PubMedCrossRefGoogle Scholar
  38. Reddy RD, Sahebarao MP, Mukherjee S, Murthy JN (1991) Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 30:409–412PubMedCrossRefGoogle Scholar
  39. Reimund JM, Allison AC, Muller CD, Dumont S, Kenney JS, Baumann R, Duclos B, Poindron P (1998) Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn’s disease and ulcerative colitis. Eur J Clin Invest 28:145–150PubMedCrossRefGoogle Scholar
  40. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57–73PubMedCrossRefGoogle Scholar
  41. Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10:2247–2258PubMedGoogle Scholar
  42. Schreck R, Albermann K, Baeuerle PA (1992) Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 17:221–237PubMedCrossRefGoogle Scholar
  43. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152PubMedCrossRefGoogle Scholar
  44. Song C, Lin A, Kenis G, Bosmans E, Maes M (2000) Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 42:157–164PubMedCrossRefGoogle Scholar
  45. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK (1999) Elevated interleukin-6 in schizophrenia. Psychiatry Res 87:129–136PubMedCrossRefGoogle Scholar
  46. Yao JK, van Kammen DP, Gurklis J (1994) Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 13:227–232PubMedCrossRefGoogle Scholar
  47. Yao JK, Reddy R, McElhinny LG, van Kammen DP (1998) Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 32:385–391PubMedCrossRefGoogle Scholar
  48. Yao JK, Reddy RD, van Kammen DP (2000) Abnormal age related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97:137–151PubMedCrossRefGoogle Scholar
  49. Yao JK, Reddy RD, van Kammen DP (2001) Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287–310PubMedCrossRefGoogle Scholar
  50. Yao JK, Sistilli CG, van Kammen DP (2003) Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69:429–436PubMedCrossRefGoogle Scholar
  51. Zalcman S, Green-Johnson JM, Murray L, Nancy DM, Dyck D, Anisman H, Greenberg AJ (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, 2, and 6. Brain Res 643:40–49PubMedCrossRefGoogle Scholar
  52. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC (2001) Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 16:325–330PubMedCrossRefGoogle Scholar
  53. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC (2002) Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57:247–258PubMedCrossRefGoogle Scholar
  54. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY (2003a) Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 117:85–88PubMedCrossRefGoogle Scholar
  55. Zhang XY, Zhou DF, Cao LY, Chen DC, Zhu FY, Wu GY (2003b) Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 62:245–250PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Xiang Yang Zhang
    • 1
    • 3
    • 5
  • Dong Feng Zhou
    • 2
  • Ling Yan Qi
    • 3
  • Song Chen
    • 3
  • Lian Yuan Cao
    • 3
  • Da Chun Chen
    • 3
  • Mei Hong Xiu
    • 3
  • Fan Wang
    • 3
  • Gui Ying Wu
    • 1
  • Lin Lu
    • 4
  • Therese A. Kosten
    • 1
  • Thomas R. Kosten
    • 1
    • 6
  1. 1.Menninger Department of Psychiatry and Behavioral SciencesBaylor College of MedicineHoustonUSA
  2. 2.Institute of Mental HealthPeking UniversityBeijingPeople’s Republic of China
  3. 3.Center for Biological PsychiatryBeijing HuiLongGuan HospitalBeijingPeople’s Republic of China
  4. 4.National Institute on Drug DependencePeking UniversityBeijingPeople’s Republic of China
  5. 5.Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of MedicineVA Medical CenterHoustonUSA
  6. 6.Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of MedicineVA Medical CenterHoustonUSA

Personalised recommendations